search
Back to results

CAD EYE Detection of Remaining Lesions After EMR

Primary Purpose

Colorectal Dysplasia, Colorectal Neoplasms

Status
Recruiting
Phase
Not Applicable
Locations
Ecuador
Study Type
Interventional
Intervention
EMR with CAD-Eye™
EMR without CAD-Eye™
Follow-up colonoscopy with CAD-Eye™
Sponsored by
Instituto Ecuatoriano de Enfermedades Digestivas
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Colorectal Dysplasia focused on measuring Artificial Intelligence, Colonoscopy, Endoscopic mucosal resection, Computer-assisted diagnosis

Eligibility Criteria

18 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients referred to our center with an indication of colonoscopy and EMR for the treatment of lesions suspicious of high-grade dysplasia and early invasive cancer.
  • Patients who authorize EMR and colonoscopy.
  • Signed informed consent

Exclusion Criteria:

  • Any clinical condition which makes EMR inviable.
  • Poor bowel preparation score defined as the total Boston bowel preparation score (BBPS) <6 and the right-segment score <2
  • Patients with more than one previous EMR
  • Lost on a three-month follow-up after EMR
  • Pregnancy or nursing

Sites / Locations

  • Carlos Robles-MedrandaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Endoscopic mucosal resection + CAD-Eye™

Endoscopic mucosal resection without CAD Eye

Arm Description

This group constitutes patients with lesions suggestive of high-grade dysplasia or early invasive cancer approached with endoscopic mucosal resection, subjected to colonoscopy + CAD-Eye™ system evaluation for the detection of remaining malignant tissue. For this group, the investigators used as a complement tool an AI system (CAD-Eye™) for the detection of remaining lesions immediately after EMR and in a three-month follow-up.

This group constitutes patients with lesions suggestive of high-grade dysplasia or early invasive cancer approached with endoscopic mucosal resection and subjected to colonoscopy. The detection of remaining lesions immediately after EMR is based on the visual impression of the expert. For this group, the investigators used as a complement tool an AI system (CAD-Eye™) only for the evaluation of the post-procedure scar to detect remaining lesions in the three-month follow-up.

Outcomes

Primary Outcome Measures

Lesions recurrence after EMR
Detection of remaining lesions immediately after EMR procedure based on endoscopist expertise (EMR without CAD-Eye™ group) or CAD-Eye™ (EMR + CAD-Eye™ group). Lesions will be confirmed by biopsy. Data will be summarized as frequencies.
Lesions recurrence in a three-month follow-up after EMR
Evaluation of CAD-Eye™ in the detection of recurrent lesions after EMR procedure. Remaining lesions detected by CAD-Eye™ in the three-month follow-up. Lesions will be confirmed by biopsy. Data will be summarized as frequencies.

Secondary Outcome Measures

Recurrence risk after EMR
Calculate de recurrence risk by the Sydney EMR recurrence tool (SERT) in a scale from 0 to 4 2 points: size of 40 mm or larger 1 point: Intraprocedural bleeding (IPB) 1 point: high-grade dysplasia (HGD) in histopathology

Full Information

First Posted
September 5, 2022
Last Updated
September 26, 2023
Sponsor
Instituto Ecuatoriano de Enfermedades Digestivas
search

1. Study Identification

Unique Protocol Identification Number
NCT05542030
Brief Title
CAD EYE Detection of Remaining Lesions After EMR
Official Title
Accuracy of CAD Eye in the Detection of Colonic Remaining Lesions After Endoscopic Mucosal Resection: a Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 12, 2022 (Actual)
Primary Completion Date
March 1, 2024 (Anticipated)
Study Completion Date
September 12, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Instituto Ecuatoriano de Enfermedades Digestivas

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
In the last decade, many innovative systems have been developed to support and improve the diagnosis accuracy during endoscopic studies. CAD-Eye™ (Fujifilm, Tokyo, Japan) is a computer-assisted diagnostic (CADx) system that uses artificial intelligence for the detection and characterization of polyps during colonoscopy. However, the accuracy of CAD-Eye™ in the recognition of remaining lesions after endoscopic mucosal resection (EMR) has not been broadly evaluated. Finally, based on the importance of complete resection of the colonic mucosal lesions, namely suspicious high-grade dysplasia or early invasive cancer, the investigators aimed to assess the accuracy of CAD-Eye™ in the detection of remaining lesions after the procedure.
Detailed Description
Nowadays, the increased polyp and adenoma detection rate, and its early treatment have reduced considerably colorectal cancer-related mortality. For lesions suspicious of high-grade dysplasia or early invasive cancer, the endoscopic mucosal resection (EMR), along with snare polypectomy, is now considered one of the established standard treatments. However, there are many ´difficult-to-treat lesions´ such as the large and fibrotic ones, which can lead to incomplete resections. Based on the above, many newly diagnostic techniques guided by artificial intelligence (AI), currently proposed to improve the polyp detection rate during colonoscopy, can be applied for the detection of remaining lesions after endoscopic treatment. CAD-Eye™ is CADx for polyp detection and characterization. It improves polyp visualization by using techniques such as blue-laser imaging (BLI-LASER), blue-light imaging (BLI-LED), and linked-color imaging (LCI). This device aimed to improve real-time polyp detection, helping experts identify multiple polyps simultaneously and common inadvertently missed lesions (flat lesions, polyps in difficult areas). CAD-Eye™ had demonstrated in previous studies an accuracy of 89% to 91.7% in polyp detection. However, few studies had demonstrated its performance in the detection of remaining lesions after EMR. The investigators aimed to take advantage of this system in the detection of remaining lesions immediately after EMR and in its endoscopic control after three months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colorectal Dysplasia, Colorectal Neoplasms
Keywords
Artificial Intelligence, Colonoscopy, Endoscopic mucosal resection, Computer-assisted diagnosis

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Non-blinded, single center, non-randomized prospective pilot study
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Endoscopic mucosal resection + CAD-Eye™
Arm Type
Experimental
Arm Description
This group constitutes patients with lesions suggestive of high-grade dysplasia or early invasive cancer approached with endoscopic mucosal resection, subjected to colonoscopy + CAD-Eye™ system evaluation for the detection of remaining malignant tissue. For this group, the investigators used as a complement tool an AI system (CAD-Eye™) for the detection of remaining lesions immediately after EMR and in a three-month follow-up.
Arm Title
Endoscopic mucosal resection without CAD Eye
Arm Type
Active Comparator
Arm Description
This group constitutes patients with lesions suggestive of high-grade dysplasia or early invasive cancer approached with endoscopic mucosal resection and subjected to colonoscopy. The detection of remaining lesions immediately after EMR is based on the visual impression of the expert. For this group, the investigators used as a complement tool an AI system (CAD-Eye™) only for the evaluation of the post-procedure scar to detect remaining lesions in the three-month follow-up.
Intervention Type
Diagnostic Test
Intervention Name(s)
EMR with CAD-Eye™
Intervention Description
Patients of group 1 undergoing Intervention 1 are subjected to an EMR with CAD-Eye™ to detect the remaining lesions immediately after the endoscopic procedure. The suspected remaining lesions in the post-procedure defect detected with CAD-Eye™ are removed and sent to pathology to confirm the diagnosis.
Intervention Type
Diagnostic Test
Intervention Name(s)
EMR without CAD-Eye™
Intervention Description
Patients of group 2, undergoing intervention 2, subjected to an EMR alone. The immediate detection of remaining lesions is based on the visual impression of the expert. The suspected remaining lesions in the post-procedure defect are removed and sent to pathology to confirm the diagnosis.
Intervention Type
Diagnostic Test
Intervention Name(s)
Follow-up colonoscopy with CAD-Eye™
Intervention Description
Patients undergoing Interventions 1 and 2, with a previous EMR, are assigned for a three-month follow-up using the CAD-Eye™ as a complementary procedure to detect remaining lesions. For the detection of residual lesions, the colonoscope with the CAD-Eye™ assistance is used during the post-procedural scar evaluation. Suspicious lesions detected are removed and sent to pathology for final diagnosis.
Primary Outcome Measure Information:
Title
Lesions recurrence after EMR
Description
Detection of remaining lesions immediately after EMR procedure based on endoscopist expertise (EMR without CAD-Eye™ group) or CAD-Eye™ (EMR + CAD-Eye™ group). Lesions will be confirmed by biopsy. Data will be summarized as frequencies.
Time Frame
up to 1 week
Title
Lesions recurrence in a three-month follow-up after EMR
Description
Evaluation of CAD-Eye™ in the detection of recurrent lesions after EMR procedure. Remaining lesions detected by CAD-Eye™ in the three-month follow-up. Lesions will be confirmed by biopsy. Data will be summarized as frequencies.
Time Frame
up to 3 months
Secondary Outcome Measure Information:
Title
Recurrence risk after EMR
Description
Calculate de recurrence risk by the Sydney EMR recurrence tool (SERT) in a scale from 0 to 4 2 points: size of 40 mm or larger 1 point: Intraprocedural bleeding (IPB) 1 point: high-grade dysplasia (HGD) in histopathology
Time Frame
up to 1 week

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients referred to our center with an indication of colonoscopy and EMR for the treatment of lesions suspicious of high-grade dysplasia and early invasive cancer. Patients who authorize EMR and colonoscopy. Signed informed consent Exclusion Criteria: Any clinical condition which makes EMR inviable. Poor bowel preparation score defined as the total Boston bowel preparation score (BBPS) <6 and the right-segment score <2 Patients with more than one previous EMR Lost on a three-month follow-up after EMR Pregnancy or nursing
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Carlos Robles-Medranda, MD FASGE
Phone
+59342109180
Email
carlosoakm@yahoo.es
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Carlos Robles-Medranda, MD FASGE
Organizational Affiliation
Instituto Ecuatoriano de Enfermedades Digestivas (IECED)
Official's Role
Principal Investigator
Facility Information:
Facility Name
Carlos Robles-Medranda
City
Guayaquil
State/Province
Guayas
ZIP/Postal Code
090505
Country
Ecuador
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carlos Robles-Medranda, MD FASGE
Phone
+59342109180
Email
carlosoakm@yahoo.es
First Name & Middle Initial & Last Name & Degree
Hannah P. Lukashok, MD
First Name & Middle Initial & Last Name & Degree
Juan Alcivar-Vasquez, MD
First Name & Middle Initial & Last Name & Degree
Miguel Puga-Tejada, MD
First Name & Middle Initial & Last Name & Degree
Maria Egas-Izquierdo, MD
First Name & Middle Initial & Last Name & Degree
Jorge Baquerizo-Burgos, MD
First Name & Middle Initial & Last Name & Degree
Martha Arevalo-Mora, MD
First Name & Middle Initial & Last Name & Degree
Domenica Cunto, MD

12. IPD Sharing Statement

Citations:
PubMed Identifier
33940578
Citation
Kliegis L, Obst W, Bruns J, Weigt J. Can a Polyp Detection and Characterization System Predict Complete Resection? Dig Dis. 2022;40(1):115-118. doi: 10.1159/000516974. Epub 2021 May 6.
Results Reference
background
PubMed Identifier
34406437
Citation
Yoshida N, Inoue K, Tomita Y, Kobayashi R, Hashimoto H, Sugino S, Hirose R, Dohi O, Yasuda H, Morinaga Y, Inada Y, Murakami T, Zhu X, Itoh Y. An analysis about the function of a new artificial intelligence, CAD EYE with the lesion recognition and diagnosis for colorectal polyps in clinical practice. Int J Colorectal Dis. 2021 Oct;36(10):2237-2245. doi: 10.1007/s00384-021-04006-5. Epub 2021 Aug 18.
Results Reference
background
PubMed Identifier
30686899
Citation
Dumoulin FL, Hildenbrand R. Endoscopic resection techniques for colorectal neoplasia: Current developments. World J Gastroenterol. 2019 Jan 21;25(3):300-307. doi: 10.3748/wjg.v25.i3.300.
Results Reference
background
PubMed Identifier
34437563
Citation
Neumann H, Kreft A, Sivanathan V, Rahman F, Galle PR. Evaluation of novel LCI CAD EYE system for real time detection of colon polyps. PLoS One. 2021 Aug 26;16(8):e0255955. doi: 10.1371/journal.pone.0255955. eCollection 2021.
Results Reference
background
PubMed Identifier
28286095
Citation
Min M, Deng P, Zhang W, Sun X, Liu Y, Nong B. Comparison of linked color imaging and white-light colonoscopy for detection of colorectal polyps: a multicenter, randomized, crossover trial. Gastrointest Endosc. 2017 Oct;86(4):724-730. doi: 10.1016/j.gie.2017.02.035. Epub 2017 Mar 9.
Results Reference
background
PubMed Identifier
27908600
Citation
Tate DJ, Desomer L, Klein A, Brown G, Hourigan LF, Lee EY, Moss A, Ormonde D, Raftopoulos S, Singh R, Williams SJ, Zanati S, Byth K, Bourke MJ. Adenoma recurrence after piecemeal colonic EMR is predictable: the Sydney EMR recurrence tool. Gastrointest Endosc. 2017 Mar;85(3):647-656.e6. doi: 10.1016/j.gie.2016.11.027. Epub 2016 Nov 28.
Results Reference
background

Learn more about this trial

CAD EYE Detection of Remaining Lesions After EMR

We'll reach out to this number within 24 hrs